Y-mAbs Therapeutics Ownership | Who Owns Y-mAbs Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Y-mAbs Therapeutics Ownership Summary


Y-mAbs Therapeutics is owned by 63.77% institutional investors, 11.50% insiders, and 24.73% retail investors. Paradigm biocapital advisors lp is the largest institutional shareholder, holding 9.49% of YMAB shares. HBM Healthcare Investments AG Ord is the top mutual fund, with 7.28% of its assets in Y-mAbs Therapeutics shares.

YMAB Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockY-mAbs Therapeutics63.77%11.50%24.73%
SectorHealthcare Stocks 279.18%10.62%-189.80%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Paradigm biocapital advisors lp4.24M9.49%$33.17M
Blackrock funding, inc. /de3.00M6.72%$23.48M
Blackrock2.94M6.71%$35.50M
Sofinnova investments2.19M4.92%$17.18M
Vanguard group2.00M4.48%$15.66M
Polar capital1.83M4.18%$22.12M
Caligan partners lp1.77M3.96%$13.84M
Geode capital management822.31K1.84%$6.44M
State street804.61K1.84%$9.72M
Pictet asset management sa756.30K1.69%$5.92M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Caligan partners lp1.77M3.51%$13.84M
Sofinnova investments2.19M1.25%$17.18M
Paradigm biocapital advisors lp4.24M1.15%$33.17M
Soleus capital management349.98K0.17%$2.74M
Boothbay fund management693.69K0.13%$5.43M
Polar capital1.83M0.13%$22.12M
Rice hall james & associates108.55K0.05%$849.94K
Quest partners27.14K0.03%$212.47K
Xtx topco20.77K0.01%$162.61K
Bridgeway capital management49.90K0.01%$390.72K

Top Buyers

HolderShares% AssetsChange
Caligan partners lp1.77M3.51%572.73K
Paradigm biocapital advisors lp4.24M1.15%150.00K
Boothbay fund management693.69K0.13%136.26K
Renaissance131.60K0.00%103.70K
Blackrock2.94M0.00%81.46K

Top Sellers

HolderShares% AssetsChange
Logos global management lp---1.00M
Cormorant asset management, lp---425.00K
D. e. shaw615.13K0.00%-172.41K
Los angeles capital management---127.55K
Acadian asset management---105.78K

New Positions

HolderShares% AssetsChangeValue
Jump financial33.38K0.01%33.38K$261.37K
Susquehanna group, llp28.49K-28.49K$223.07K
Proshare advisors12.64K0.00%12.64K$99.01K
Simplex trading1.78K-1.78K$13.00K
Skopos labs127.000.00%127.00$995.00

Sold Out

HolderChange
Capital performance advisors llp-3.00
Nelson, van denburg & campbell wealth management group-8.00
Allspring global investments-8.00
Parallel advisors-18.00
Us bancorp \de\-23.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2025103-8.85%28,762,9250.03%631.54%581.75%27-12.90%
Dec 31, 2024107-0.93%25,429,341-1.21%561.71%52-8.77%3110.71%
Sep 30, 202410811.34%25,741,8205.70%571.88%5711.76%28-20.00%
Jun 30, 202496-3.03%24,352,7925.85%552.00%5113.33%34-20.93%
Mar 31, 2024996.45%23,007,88413.95%522.46%45-4.26%4338.71%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
HBM Healthcare Investments AG Ord3.30M7.28%-
Polar Capital Biotech S Inc1.50M3.31%-
Vanguard US Total Market Shares ETF1.04M2.30%-
Vanguard Total Stock Mkt Idx Inv1.04M2.30%-
iShares Russell 2000 ETF936.19K2.07%459.00
Vanguard Institutional Extnd Mkt Idx Tr500.90K1.11%-
SPDR® S&P Biotech ETF438.23K0.97%-2.67K
Pictet Biotech390.64K0.88%390.64K
Pictet-Biotech P USD381.85K0.84%-14.94K
Fidelity Small Cap Index375.81K0.83%1.98K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 07, 2025Rossi Michael J PRESIDENT & CEOSell$20.37K
Mar 07, 2025Gad Thomas CHIEF BUSINESS OFFICERSell$56.54K
Sep 13, 2024Gad Thomas CHIEF BUSINESS OFFICERSell$875.55K
Sep 16, 2024Gad Thomas CHIEF BUSINESS OFFICERSell$389.10K
Aug 28, 2024Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICERSell$768.50K

Insider Transactions Trends


DateBuySell
2025 Q2--
2025 Q1-2
2024 Q3-4
2024 Q2-7
2024 Q1-3

YMAB Ownership FAQ


Who Owns Y-mAbs Therapeutics?

Y-mAbs Therapeutics shareholders are primarily institutional investors at 63.77%, followed by 11.50% insiders and 24.73% retail investors. The average institutional ownership in Y-mAbs Therapeutics's industry, Biotech Stocks , is 63.96%, which Y-mAbs Therapeutics falls below.

Who owns the most shares of Y-mAbs Therapeutics?

Y-mAbs Therapeutics’s largest shareholders are Paradigm biocapital advisors lp (4.24M shares, 9.49%), Blackrock funding, inc. /de (3M shares, 6.72%), and Blackrock (2.94M shares, 6.71%). Together, they hold 22.92% of Y-mAbs Therapeutics’s total shares outstanding.

Does Blackrock own Y-mAbs Therapeutics?

Yes, BlackRock owns 6.71% of Y-mAbs Therapeutics, totaling 2.94M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 35.5M$. In the last quarter, BlackRock increased its holdings by 81.46K shares, a 2.85% change.

Who is Y-mAbs Therapeutics’s biggest shareholder by percentage of total assets invested?

Caligan partners lp is Y-mAbs Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.51% of its assets in 1.77M Y-mAbs Therapeutics shares, valued at 13.84M$.

Who is the top mutual fund holder of Y-mAbs Therapeutics shares?

HBM Healthcare Investments AG Ord is the top mutual fund holder of Y-mAbs Therapeutics shares, with 7.28% of its total shares outstanding invested in 3.3M Y-mAbs Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools